11

Solagran CEO Report

AGM 10th August 2016

Dr. Darren Schliebs

22

SOLAGRAN “SNAPSHOT”

x Small cap healthcare with near-term growth potentialx Re-launch (IPO) late CY 2016

x Bioeffectives® – unique, proprietary productsx Biologically-active galenical substances x High nutrient and therapeutic propertiesx Patented processes – first ever manufacturing facility at scalex Isolated, characterised and first-to-market polyprenols

x OTC/natural supplementsx Fast to market & high marginx Huge market opportunity

x Company Assets / Attributesx Largely Debt free* with break even planned FY 2017x Granted patents x Two company-owned production facilities

* Minor debt and trade creditors excluded

33

CORE BIOEFFECTIVES

Bioeffective A

Used in TGA-approved therapeutic productsConifer green needle complexPotent antioxidantApprovals in Australia, Russia, Singapore, Malaysia and UAE

Used in TGA-approved therapeutic productsHigh in ironApprovals in Australia, Russia and Singapore

Used in a registered pharmaceutical Ropren® (Russia)High purity and concentration prenolsFood, supplement and pharmaceutical gradesApprovals in Russia and Singapore

Bioeffective R Bioeffective I

44

Bioeffective Products / Brands Customers Markets Examples

Bioeffective A Taiga Professional (previously Bioeffective A And/orBioeffective gel

Integria HealthcareOborne HealthPulseMed

AustraliaAustraliaAustraliaUAE

CGNC(“Raw material”)

UnileverOthers

RussiaEastern Europe

NuvaPine A320NuvaPine A160

Nuvanta (Zuellig Group)

Malaysia

Bioeffective R RoprenAbieprenols

Pharma supply RussiaC.I.S./Eastern

Oleopren ArtLife RussiaEastern Europe

Bioeffective I Taiga Professional Siberian Red

Integria HealthcareOborne Health

Australia

Australia

Phytococktails Retail Russia

Several Bioeffectives

Personal care ingredients

Unilever & others

RussiaEastern Europe

CUSTOMERS & MARKETS

55

Immediate

• Grow existing Sales of Finished Goods in existing and expanding markets

• Meet large customer orders for Bioeffective “ingredients”

Near Term

• Launch prenols in Asia, Australia, online

• Expanded sales to ingredient costumers made possible by CAPEX

• Product development / combinations and new formulations

Future High-Value

• Additional clinical data to address key indications including• NASH and other liver

conditions• Cognitive & cardio

applications• H. pylori / Gut Health• Supportive therapies

GROWTH OPPORTUNITIES:

66

Solagran Bioeffectives are being incorporated in Unilever Oral Care Products

x Unilever high-volume purchaser of Solagran productsx Extensive trials found Bioeffectives to be more efficacious for general oral care

and selected specific conditions than existing products on the marketx Solagran achieved “Reliable supplier” status with Unilever

x Can now sell to any Unilever plant / blender globally

FOREST BALM PRODUCTS INCLUDE:Balsam for gums & Medicated prophylactic toothpaste

IMMEDIATE OPPORTUNITYIncrease supply agreement Unilever Russia

77

BRINGING BIOEFFECTIVES TO THE WORLDPROPOSED FULFILMENT: Australia – Singapore/Asia/World

Raw Materials from the Siberian Taiga forests

Finished Goods Manufactured in Australia

Distribution from Australia and (potentially) Singapore

Growth through• New products in Malaysia• New Registrations in Singapore• New Registrations in Indonesia• Online sales• Russian opportunities

(as described)

IMMEDIATE AND NEAR-TERM OPPORTUNITIES

88

BIO

EFF

EC

TIV

ER

Chronic liver disease:• Liver cirrhosis• Liver fibrosis• NAFLD / NASH

Lipid metabolism• Cholesterol

Neurodegenerative disorders• Dementia• Alzheimer’s disease

BIO

EFF

EC

TIV

EA

AntimicrobialAntifungalCold and Flu

H pylori • infection and

conditions

FUTURE OPPORTUNITIES THROUGH EXPLOITING SELECTED KEY RESEARCH

BRAIN

99

BIO

EFF

EC

TIV

ER

Chronic liver disease:• Liver cirrhosis• Liver fibrosis• NAFLD / NASH

Chronic Liver damage affects up to 20% of population. Liver cancer is one of fastest growing diseases worldwide.

Ropren® has potential clinical applications for multiple liver conditions.

Lipid metabolism• Cholesterol

There is mounting evidence Statins increase the risk of diabetes, dementia and myopathy

Ropren has been demonstrated to normalise lipid metabolism and lower with excellent safety.

Neurodegenerative disorders• Dementia• Alzheimer’s disease

Estimated 65.7 million with dementia in 2030 (doubling from 2010). Cognitive affects many more.

Human data found that Ropren significantly increased spatial memory , memory and speed of retrieval of information with excellent safety.

BIO

EFF

EC

TIV

EA

AntimicrobialAntifungalCold and Flu

Bioeffective A has efficacy against most infectious agents including methicillin-resistant strains (MRSA & MRSE), and common fungi in women’s health Candida strains, plus Trichomonas vaginalis etc. and childhood diseases. Cold therapy is supported by human data including treatment of upper respiratory infections.

H pylori • infection and

conditions

CGNC (Bioeffective A) reduces precancerous lesions and suppresses H. pylori significantly reduced heartburn, dyspepsia, gastritis and duodenal stomach

FUTURE OPPORTUNITY THROUGH EXPLOITING SELECTED KEY RESEARCH

1010

Year 2011 2012 2013 2014 2015Sales 1,019,383 1,813,155 1,610,255 2,085,725 2,533,081

+77.9% -11.2% +29.5% +21.5%Other 194,518 338,174 730,650 461,968 584,007Total 1,213,901 2,151,329 2,340,905 2,547,693 3,117,088

* All amounts shown in this and subsequent slides are AUD

REVENUE OF SOLAGRAN GROUP

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

20152014201320122011

Sales Revenue

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

20152014201320122011

Total Revenue

1111

Year (FY) 2015

Total incomings 3,117,088

Changes in inventory of finished and WIP + - 2,360,536

Raw Materials and consumables - 417,699

Finance expenses - 420,467Other expenses - 17,669

Admin, salaries, R&D - 2,057,217Non-cash items* - 4,285,501

Loss Before Income Tax +(excluding some non-cash items*) -6,441,971

* Non-cash items including: depreciation, impairment and unrealised Fx gains/losses+ Change in inventory is a non-cash item here, relating to inventory level over the period. If change in inventory is also excluded, the $2.16m loss becomes approximately “break even”.

SUMMARY 2015 P&L OF SOLAGRAN GROUPPath towards profitability

Also a non-cash item and drives

loss

Loss same order of

magnitude as inventory/WIP

changes

2015(less exclusions*)

3,117,088

- 2,360,536

- 417,699

- 420,467- 17,669

-2,057,217Excluded

-2,156,500

Remove selectednon-cash items

1212

IMPROVING BALANCE SHEET

Final position available in 2016 accounts (pending)

• Nil debt in convertible notes

• Retired bank debt

• Reduced trade and other payables

• Net Assets / Shareholder equity improvement

1313

Now

• Appointed service providers• Lawyer

(DD/IPO)• CFO• Investigating

accountant / auditor

• New investor repaid debt and implemented CAPEX

• 2016 Accounts and prospectus under preparation

Offering to market

• Small cap IPO • Company with

revenues and blue sky opportunity

• Incomings growth YOY for 5 yrs

• Debt free• Major

international customers including Unilever

• Significantly improved balance sheet

Required

• Audited 2016 FY accounts

• Prospectus• Funding offer

under prospectus for $4m - $6m

• ASX review• ASIC review• IPO / re-list end

CY 2016

IPO/re-list*

• Cash at bank• Focus on

• Contracts and revenue growth

• Market and product development

• Sales and marketing

• Governance and communication

• Targeting profitability during CY 2017

* Subject to legal advice and ASX approval

NEXT STEPS - “RE-IPO” ON ASX WITH RAISE*

1414

• Improved Sales and Marketing

• Upgrade of facilities to match business growth

• Development of new products and markets to expand the reach of Bioeffectives

• Focussed regulatory and clinical trial program to assist the company to promote products to address specific diseases or conditions

USE OF FUNDS FROM RAISING

* TBC

1515

• Business has made significant progress• Landmark Supply Agreement with Global MNC Unilever grows• Sales revenue has positive trend

• e.g. up 21% and 29% YOY over FY2014 and FY2015• Successfully Raised $3.86m Capital – retired debts & expanded production facilities• All reporting requirements up to date

• 2016 Accounts currently under prep/audit• All convertible notes have been converted to equity• Four patents granted in USA in 2015

• New management capability• Added new CEO since ceased trading • New Chairman-Designate appointed as NED, to assume Chair after IPO

• Relisting – target back on ASX end 2016• PRENOLICA

POISED FOR REVENUE GROWTHAND RE-IPO

1616

Thank you

1717

Appendices (if required)

1818

TOP 20 SHAREHOLDERS (8th August 2016)

* Final numbers subject to review.

1. GASMERE PTY LIMITED 222,204,001 19.452. DR VAGIF SOULTANOV 202,734,349 17.743. ACE AIM PTE LTD 140,583,585 12.304. BEREG LTD 53,333,334 4.675. ABU SAHID MOHAMED 50,000,000 4.386. BEACON PITCH PTY LTD 47,506,415 4.167. BASE JUMPER PTY LTD 47,500,000 4.168. AMMF INVESTMENTS PTY LTD 38,333,333 3.369. SOLALIFE PTY LTD 28,000,000 2.4510. MR EKA TJANDRANEGARA 25,000,000 2.1911. HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 17,695,467 1.5512. JAMES ST EQUITIES PTY LTD 14,700,000 1.2913. CITICORP NOMINEES PTY LIMITED 10,256,237 0.9014. HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED <EUROCLEAR BANK SA NV A/C> 9,565,832 0.8415. MR ERWIN WEINZINGER 5,833,333 0.5116. MR GAVIN PETER HERHOLDT 5,320,000 0.4717. J P MORGAN NOMINEES AUSTRALIA LIMITED 5,245,668 0.4618. MR FIRDAUS BASYROV 5,097,431 0.4519. AGIE SALLY LAU SIE SIEUNG 5,000,000 0.4420. EASTOK PTY LTD 4,921,034 0.43

Totals: Top 20 holders of ORDINARY SHARES 938,830,019 82.17Total Remaining Holders Balance 203,705,148 17.83

1919

Patent Family / Technology Australia USA Russia Others

* CORE TECHNOLOGICAL PATENT -Vegetable Raw Materials" - Protects unique extraction technology.

Granted Granted US8,969,5173 March 2015

Granted

Granted:LATVIA Canada Indonesia

CELL SAP TECHNOLOGICAL PATENT -producing vegetable cell sap concentrate Granted

Granted US9,173,9113 November 2015

Granted Granted:Malaysia

THERAPEUTIC USE PATENT-Bioeffective R in the treatment of DEMENTIA/ALZHEIMER'S

GrantedGranted US8,987,33824 March 2015

Granted

Granted:EPO - Individual jurisdictions to be nominated

THERAPEUTIC USE PATENT- Bioeffectivetreatment of ALCOHOLISM/NARCOTIC DEPENDANCE

Granted Under Examination Granted

Granted:EPO - Individual jurisdictions to be nominated

THERAPEUTIC USE PATENT- Bioeffective the treatment of DISEASES CAUSED BY EXCESSIVE MAO*

GrantedGranted US8,952,07410 Feb 2015

Granted

THERAPEUTIC USE PATENT- Bioeffective the treatment of HELICOBACTER PYLORI Under Examination Under Examination Granted Granted:

Indonesia

THERAPEUTIC USE PATENT- Bioeffective the treatment of TRICHOMONAS Under Examination Under Examination Granted Accepted

The above patents are also pending / under examination variously in selected jurisdictions such as Europe, Canada, Indonesia, Malaysia and India* MAO (L-Monoamine oxidases). Excess MAO has been indicated in cognitive dysfunction, depression, mental illnesses

• Four US Patents granted in 2015

INTELLECTUAL PROPERTY UPDATE